Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Yi-Jun Jian"'
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0254000 (2021)
Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second leading cause of cancer-related deaths in the world. It has been the most prevalent malignancy in Taiwan for consecutive thirteen years. Despite the diversity of i
Externí odkaz:
https://doaj.org/article/e22598d3606849828cb92b6cf3e1279d
Autor:
Yi-Jun Jian, Yun-Wei Lin, Yi-Shuan Peng, Hao-Yu Zheng, Chia-Li Wei, Jyh-Cheng Chen, Chia-Hung Wu, Wen-Ching Chen, Ya-Ting Cheng, Chun-Liang Tung
Publikováno v:
Experimental Cell Research. 357:59-66
Erlotinib (TarcevaR) is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor in the treatment of human non-small cell lung cancer (NSCLC). Salinomycin, a polyether antibiotic, has been promising a novel therapeutic agent for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d0c30c1689345900b15145bf2edb76a
https://doi.org/10.1016/j.yexcr.2017.04.026
https://doi.org/10.1016/j.yexcr.2017.04.026
Autor:
Tai-Jing Wang, Po-Yuan Chang, Yun-Wei Lin, Chun-Liang Tung, Yun-Ting Jian, Jhan-Jhang Syu, Chien-Yu Chen, Yi-Jun Jian
Publikováno v:
Experimental Cell Research. 334:126-135
Gefitinib (Iressa(R), ZD1839) is a selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that blocks growth factor-mediated cell proliferation and extracellular signal-regulated kinases 1/2 (ERK1/2) and AKT signaling activat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043758af41a1996b4e6701bfb437611a
https://doi.org/10.1016/j.yexcr.2015.01.016
https://doi.org/10.1016/j.yexcr.2015.01.016
Autor:
Ting-Yu Wo, Chun-Liang Tung, Yun-Wei Lin, Chien-Yu Chen, Yi-Jhen Huang, Jhan-Jhang Syu, Sheng-Chieh Tseng, Hsien-Chun Chiu, Yi-Jun Jian, Yun-Ting Jian
Publikováno v:
Experimental Cell Research. 322:345-354
Elevated heat shock protein 90 (Hsp90) expression has been linked to poor prognosis in patients with non-small cell lung cancer (NSCLC). The multitargeted antifolate pemetrexed has demonstrated certain clinical activities against NSCLC. However, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8450710e01970a3546bcb1e8a6592147
https://doi.org/10.1016/j.yexcr.2014.02.002
https://doi.org/10.1016/j.yexcr.2014.02.002
Autor:
Hsien-Chun Chiu, Ting-Yu Wo, Jen-Chung Ko, Chien-Yu Chen, Yun-Wei Lin, Jhan-Jhang Syu, Yi-Jhen Huang, Yun-Ting Jian, Yi-Jun Jian
Publikováno v:
Biochemical Pharmacology. 88:119-127
Tamoxifen is a triphenylethylene nonsteroidal estrogen receptor (ER) antagonist used worldwide as an adjuvant hormone therapeutic agent in the treatment of breast cancer. However, the molecular mechanism of tamoxifen-induced cytotoxicity in non-small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfc5f956b08fd3525d60c97e1c0fdaa9
https://doi.org/10.1016/j.bcp.2014.01.010
https://doi.org/10.1016/j.bcp.2014.01.010
Autor:
Yun-Ting Jian, Yi-Jun Jian, Yi-Jhen Huang, Ting-Yu Wo, Chien-Yu Chen, Yu-Ching Huang, Yun-Wei Lin, Sheng-Chieh Tseng, Hsien-Chun Chiu, Jen-Chung Ko, Jhan-Jhang Syu, Huang-Jen Chen
Publikováno v:
Lung Cancer. 82:397-406
Objectives Gefitinib, a quinazoline-derived tyrosine kinase inhibitor, has anti-tumor activity in vivo and in vitro . Human MutS homologue-2 (MSH2) plays a central role in promoting genetic stability by correcting DNA replication errors. The present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b9c95d52d188bdb859c99bc1920519a
https://doi.org/10.1016/j.lungcan.2013.09.011
https://doi.org/10.1016/j.lungcan.2013.09.011
Autor:
Yun-Wei Lin, Jen-Chung Ko, Huang-Jen Chen, Ruey-Shyang Chen, Sheng-Chieh Tseng, Yi-Jhen Huang, Hsien-Chun Chiu, Ting-Yu Wo, Yu-Ching Huang, Yi-Jun Jian, Wei-Ting Lee
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology. 386:1047-1059
The multitargeted antifolate pemetrexed has demonstrated certain clinical activities against nonsmall cell lung cancer (NSCLC). Resveratrol (3,5,4-trihydroxy-trans-stilbene) is a polyphenol found in grapes and other plants and has great potential as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a85c991883e8d9d6a3f20f0b7be91ff9
https://doi.org/10.1007/s00210-013-0905-9
https://doi.org/10.1007/s00210-013-0905-9
Autor:
Chun-Liang Tung, Tai-Jing Wang, Hao-Yu Zheng, Kai-Sheng Liao, Wen-Ching Chen, Jyh-Cheng Chen, Yi-Jun Jian, Yun-Wei Lin, Po-Yuan Chang
Publikováno v:
Naunyn-Schmiedeberg's archives of pharmacology. 389(6)
Cisplatin is a well-studied and widely used chemotherapeutic agent and is effective in the treatment of the advanced human non-small cell lung cancer (NSCLC). Curcumin is a yellow pigment derived from the rhizome of Curcuma longa and has been proved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82067235891de61e64604705ae672eaa
https://pubmed.ncbi.nlm.nih.gov/27026405
https://pubmed.ncbi.nlm.nih.gov/27026405
Autor:
Yun-Ting Jian, Jyh-Cheng Chen, Tai-Jing Wang, Hao-Yu Zheng, Yun-Wei Lin, Jhan-Jhang Syu, Po-Yuan Chang, Chien-Yu Chen, Wen-Ching Chen, Jen-Chung Ko, Yi-Jun Jian
Publikováno v:
Biochemical pharmacology. 97(3)
Minocycline is a semisynthetic tetracycline derivative; it has anti-inflammatory and anti-cancer effects distinct from its antimicrobial function. However, the molecular mechanism of minocycline-induced cytotoxicity in non-small cell lung cancer (NSC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e09e4c5b4c6795859a156be0f6696aab
https://pubmed.ncbi.nlm.nih.gov/26212550
https://pubmed.ncbi.nlm.nih.gov/26212550